Clinical Trial Update: DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5% [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating tafluprost 0.0015% alone and in combination with timolol 0.5% for open-angle glaucoma and ocular hypertension. Results were posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• Tafluprost ophthalmic solution 0.0015% (tafluprost)
• Timolol ophthalmic solution 0.5% (Timolol)

Snippet

Sponsor: Santen Pharmaceutical Co., Ltd. | Conditions: Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2015-05-14